Mark Kapperman, OD
Optometrist · Chattanooga, TNNPI 1295728863
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (33.3%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Alcon accounts for 85.7% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $9,870 and has fallen 91.5% since, to $838 in 2025. Among optometrist clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 274 payments — averaging $98.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$23K
- Coopervision Inc.$1K
- Tarsus Pharmaceuticals, Inc.$356
- Oyster Point Pharma, Inc.$277
- Bausch & Lomb, A Division Of Bausch Health US, LLC$255
- ABB Con-cise Optical Group LLC$234
- plus $1K from 21 others
What the payments were for
- Consulting fees$8,95533%
- Speaking & faculty fees$7,12526%
- Travel & lodging$4,34116%
- Food & beverage$6,43824%
- Gifts$390%
- Entertainment$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 138 | $23,052 |
| Coopervision Inc. | 32 | $1,302 |
| Tarsus Pharmaceuticals, Inc. | 11 | $356 |
| Oyster Point Pharma, Inc. | 11 | $277 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 10 | $255 |
| ABB Con-cise Optical Group LLC | 6 | $234 |
| AbbVie(2 entities) | 11 | $234 |
| Novartis | 11 | $191 |
| Bausch & Lomb Americas Inc. | 4 | $162 |
| Mallinckrodt Hospital Products Inc. | 6 | $129 |
| Johnson & Johnson Vision Care, Inc. | 5 | $85 |
| Kala Pharmaceuticals, Inc. | 5 | $82 |
| Biotissue Holdings Inc. | 4 | $82 |
| Optos, Inc. | 2 | $70 |
| Carl Zeiss Meditec USA, Inc. | 1 | $60 |
| Shire North American Group Inc | 3 | $54 |
| Amgen | 2 | $42 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Dompe US, Inc. | 2 | $37 |
| Topcon Healthcare, Inc. | 1 | $33 |
| Maculogix, Inc. | 1 | $25 |
| Sun Pharmaceutical Industries Inc. | 1 | $25 |
| Thea Pharma Inc. | 1 | $24 |
| LKC Technologies, Inc. | 1 | $16 |
| Alcon Research LLC | 1 | $16 |
| Sight Sciences, Inc. | 1 | $16 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAILIES$8,966
- AIR OPTIX$6,854
- Precision 1$6,168
- TOTAL30$6,029
- DAILIES TOTAL1$5,907
- AIR OPTIX Aqua$3,618
- Dailies Aqua Comfort Plus$1,523
- DAILIES TOTAL1 Multifocal$815
- Biofinity Contact Lens$500
- XDEMVY$121
- Contact Lens$120
- MyDay Contact Lens$113
- ULTRA$108
How this compares
$26,912 in reported general payments places this provider in the 95th percentile of 1,122 optometrist providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XdemvyLotilaner | 11 | $20,699 |
| LumiganBimatoprost | 37 | $18,357 |
| RestasisCyclosporine | 12 | $12,889 |
| XiidraLifitegrast | 14 | $12,860 |
| Latanoprost | 183 | $2,656 |
| Timolol Maleate | 32 | $828 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 18 | $627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis | $234 | $31,24549 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $356 | $20,69911 claims |
| Bausch & Lomb Americas Inc.Xiidra | $162 | $12,86014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,122 optometrist providers in Tennessee.
Other optometrist in Chattanooga
- Troy WhiteChattanooga$8K
- Luckson PrevilChattanooga$7K
- Christopher LievensMemphis$566K
- Whitney HauserMemphis$330K
- Torrey CarlsonKingsport$192K
- Frances BynumMartin$162K
- Melvin FriedmanMemphis$108K
- Kurt SteeleNewport$90K
- Jennifer DrakeColumbia$84K
- Travis JohnsonMurfreesboro$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.